AMPK signaling pathway, a fuel sensor and regulator, promotes ATP-producing and inhibits ATP-consuming pathways in various tissues. AMPK is a heterotrimer composed of alpha-catalytic and beta and gamma-regulatory subunits. Humans and rodents have two alpha and beta and three gamma isoforms; some genes are subject to alternative splicing increasing the range of possible heterotrimer combinations. Cellular stresses that inhibit ATP production or increase its consumption change the AMP:ATP ratio and activate the pathway. AMPK activation by AMP is not completely understood; the current model states that binding of AMP to the gamma subunit leads to conformational changes that allosterically activate AMPK and render phosphorylated-Thr172 unavailable for inhibitory dephosphorylation. ATP antagonizes the effect of AMP; both AMP and ATP bind in a mutually exclusive manner to the Bateman (CBS) domains of the gamma subunit. The upstream kinase, known as Lkb1, is a complex of one catalytic and two regulatory subunits; Lkb1 is believed to be ‘constitutively active’. In certain cell types, Thr172 can be phosphorylated by calmodulin-dependent protein kinase kinases (CAmKK), in turn activated by calcium. A well known role of AMPK is in the regulation of lipid metabolism; it stimulates fatty acids oxidation and inhibits their synthesis. Phosphorylation by AMPK inhibits acetyl-CoA carboxylase (ACC) and results in reduced levels of malonyl-CoA product. Malonyl CoA is a substrate in the de novo synthesis of fatty acids and fatty acids elongation. Importantly, it is also an inhibitor of the carnitine palmitoyl transferase I, required for the transfer of primed cytosolic fatty acids into the mitochondrion where they can undergo degradative beta-oxidation. AMPK inhibits mTOR signaling pathway by activating Tsc2 and downstream of Tsc2 by inhibiting Raptor component of mTOR complex 1 [note that this effect is opposite to Tsc2 phosphorylation and inactivation by PI3K-Akt signaling downstream of insulin]. AMPK is also involved in promoting glucose uptake and utilization and integrates adipokynes and hormonal signals in both the hypothalamus and the periphery with potential impact on energy expenditure and uptake by molecular mechanisms that remain to be established. Due to its roles in fuel regulation, the AMPK pathway is regarded as a potential therapeutic target for diabetes type II, obesity and metabolic syndrome. As a note, drugs used in the treatment of insulin resistance and diabetes can activate AMPK.
AMP-activated protein kinase (AMPK) plays a key role as a master regulator of cellular energy homeostasis. The kinase is activated in response to stresses that deplete cellular ATP supplies such as low glucose, hypoxia, ischemia and heat shock. It exists as a heterotrimeric complex composed of a catalytic α subunit and regulatory β and γ subunits. Binding of AMP to the γ subunit allosterically activates the complex, making it a more attractive substrate for its major upstream AMPK kinase, LKB1. Several studies indicate that signaling through adiponectin, leptin and CAMKKβ may also be important in activating AMPK.
As a cellular energy sensor responding to low ATP levels, AMPK activation positively regulates signaling pathways that replenish cellular ATP supplies. For example, activation of AMPK enhances both the transcription and translocation of GLUT4, resulting in an increase in insulin-stimulated glucose uptake. In addition, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis via inhibition of ACC and activation of PFK2. AMPK negatively regulates several proteins central to ATP consuming processes such as TORC2, glycogen synthase, SREBP-1 and TSC2, resulting in the downregulation or inhibition of gluconeogenesis, glycogen, lipid and protein synthesis. Due to its role as a central regulator of both lipid and glucose metabolism, AMPK is considered to be a key therapeutic target for the treatment of obesity, type II diabetes mellitus, and cancer.
Comments
HomologyConvert
This pathway was inferred from Homo sapiens pathway WP1403(79471) with a 95.0% conversion rate.
Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, Van den Berghe G, Carling D, Hue L; ''Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia.''; Curr Biol, 2000 PubMedEurope PMCScholia
Carling D, Hardie DG; ''The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase.''; Biochim Biophys Acta, 1989 PubMedEurope PMCScholia
Lee WJ, Kim M, Park HS, Kim HS, Jeon MJ, Oh KS, Koh EH, Won JC, Kim MS, Oh GT, Yoon M, Lee KU, Park JY; ''AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1.''; Biochem Biophys Res Commun, 2006 PubMedEurope PMCScholia
Findlay GM, Harrington LS, Lamb RF; ''TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation?''; Curr Opin Genet Dev, 2005 PubMedEurope PMCScholia
Fu A, Screaton RA; ''Using kinomics to delineate signaling pathways: control of CRTC2/TORC2 by the AMPK family.''; Cell Cycle, 2008 PubMedEurope PMCScholia
Shaw RJ; ''LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.''; Acta Physiol (Oxf), 2009 PubMedEurope PMCScholia
Inoki K, Zhu T, Guan KL; ''TSC2 mediates cellular energy response to control cell growth and survival.''; Cell, 2003 PubMedEurope PMCScholia
Cheng A, Saltiel AR; ''More TORC for the gluconeogenic engine.''; Bioessays, 2006 PubMedEurope PMCScholia
Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N; ''Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.''; J Biol Chem, 2005 PubMedEurope PMCScholia
Halse R, Fryer LG, McCormack JG, Carling D, Yeaman SJ; ''Regulation of glycogen synthase by glucose and glycogen: a possible role for AMP-activated protein kinase.''; Diabetes, 2003 PubMedEurope PMCScholia
Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N; ''4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway.''; Genes Dev, 1998 PubMedEurope PMCScholia
Viana R, Aguado C, Esteban I, Moreno D, Viollet B, Knecht E, Sanz P; ''Role of AMP-activated protein kinase in autophagy and proteasome function.''; Biochem Biophys Res Commun, 2008 PubMedEurope PMCScholia
Murgia M, Jensen TE, Cusinato M, Garcia M, Richter EA, Schiaffino S; ''Multiple signalling pathways redundantly control glucose transporter GLUT4 gene transcription in skeletal muscle.''; J Physiol, 2009 PubMedEurope PMCScholia
Hong YH, Varanasi US, Yang W, Leff T; ''AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability.''; J Biol Chem, 2003 PubMedEurope PMCScholia
Holmes BF, Sparling DP, Olson AL, Winder WW, Dohm GL; ''Regulation of muscle GLUT4 enhancer factor and myocyte enhancer factor 2 by AMP-activated protein kinase.''; Am J Physiol Endocrinol Metab, 2005 PubMedEurope PMCScholia
Hue L, Beauloye C, Marsin AS, Bertrand L, Horman S, Rider MH; ''Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways.''; J Mol Cell Cardiol, 2002 PubMedEurope PMCScholia
Try the New WikiPathways
View approved pathways at the new wikipathways.org.Quality Tags
Ontology Terms
Bibliography
History
External references
DataNodes
Annotated Interactions
No annotated interactions